Quarterly report pursuant to Section 13 or 15(d)

Acquisition (Tables)

v3.5.0.2
Acquisition (Tables)
 9 Months Ended
Sep. 30, 2016
Business Combinations [Abstract]  
Schedule of Assets and Liabilities Acquired
The purchase price allocation is preliminary and subject to change, as an analysis has not been completed as of the date of this report as Venaxis is still reviewing all of the underlying assumptions and calculations used in the allocation. However, the table below summarizes the provisional estimated fair values assigned to the assets and liabilities acquired:
 
Cash and cash equivalents
  
$
17,000
  
Accounts receivable
    
21,000
  
Inventory
    
413,000
  
Prepaid and other assets
    
52,000
  
Equipment
    
93,000
  
Intangible rights acquired
    
2,312,000
  
Accounts payable
    
(118,000
)
Accrued and other liabilities
    
(187,000
)
Non-controlling interest
    
(26,000
)
Purchase price
  
$
2,577,000
  
Schedule of Pro Forma Results of Operations
The following unaudited pro forma information presents the results of operations for the nine months ended September 30, 2016 and 2015, as if the acquisition of BiOptix had occurred on each of January 1, 2016 and 2015, respectively:
 
 
Year to Date period ended September 30,
  
 
2016
  
2015
  
Total revenues
  
$
191,577
      
639,944
  
Net (loss) attributable to Venaxis
  
$
(4,527,483
)
  
$
(8,380,348
)
Basic and diluted loss per share
  
$
(1.01
)
  
$
(1.86
)